PMC:7600245 / 11363-11716
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T39 | 135-143 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T104 | 29-35 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
| T105 | 37-38 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T105 | 247-257 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T106 | 258-263 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T107 | 347-352 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T84 | 0-353 | Sentence | denotes | As far as clinical trials in humans, a randomized, placebo-controlled, double-blind trial in hospitalized adults (n = 236) with severe COVID-19 in China initially revealed that the median time to improvement was not substantially different in the remdesivir group (200 mg on the first day, and then 100 mg/day for 9 days) from that of the placebo group. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 291 | 29-35 | Species | denotes | humans | Tax:9606 |
| 303 | 247-257 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 318 | 135-143 | Disease | denotes | COVID-19 | MESH:C000657245 |